Leem to fight French med ed tax and sales rep limits; Prescrire wants public clinical trials
This article was originally published in Scrip
Executive Summary
The planned root-and-branch reform of the French medicines regulatory system has been generally welcomed as overdue and pretty much in line with trends at European level, such as the shift to more transparency in procedures and towards requiring comparative trials for new drug approvals.